Abstract:Vancomycin is widely used in neonatal sepsis but proportion of newborn reaching recommended concentration is variable. Fluid status impact on vancomycin level remains understudied. We aimed to study fluid factors impacting vancomycin concentration at 24 h of treatment. We performed a prospective and retrospective observational monocentric study of NICU patients requiring a vancomycin treatment. We used a continuous infusion protocol, with age-appropriate loading and maintenance doses. Vancomycin target serum concentration after 24 h (C24h) was above 20 mg/L. Demographic, infections, and organ failure variables were analyzed as potential predictors of C24h. Over the study period, 70 infective episodes in 52 patients were included. At treatment initiation, the median post-natal age was 12.5 days (IQR 7-23), post menstrual age 30 weeks (IQR 28-35), and median weight 1140 g (IQR 835-1722). Germs isolated were mainly gram-positive with 73.5% being coagulase-negative Staphylococci. Median C24h was 18.7 mg/L (IQR 15.4-22.4). Overall, 41 (58.6%) treatments had a C24h < 20 mg/L. After multivariate analysis, higher creatinine level (OR 1.03 (95% CI 1.002-1.06)) was associated with C24h ≥ 20 mg/L; weight gain the day before infection (OR 0.21 (95% CI 0.05-0.79)) and positive biomarkers of inflammation (OR 0.22 (0.05-0.94)) were associated with C24h < 20 mg/L. Conclusion: Vancomycin C24h was underdosed in 60% of patients and factors linked to changes in vancomycin pharmacokinetic such as volume of distribution and clearance, linked to creatinine level, inflammation, or weight gain, were identified. What is known: • Adjustment of vancomycin regimen remains difficult due to inter- and intra-individual variability of vancomycin pharmacokinetics. • Impact of fluid status on vancomycin concentration in critically ill neonates is incompletely studied. What is new: • Proportion of patients with adequate vancomycin concentration using a target adapted to nosocomial gram-positive bacteria MIC is low. • We confirmed the role of creatinine level and report two new factors associated with low vancomycin concentration: presence of systemic inflammation and weight gain.

Variation in vancomycin dosing and therapeutic drug monitoring practices in neonatal intensive care units

Vancomycin Continuous Infusion in Neonates: Dosing Optimisation and Therapeutic Drug Monitoring

Optimisation of Vancomycin Exposure in Neonates Based on the Best Level of Evidence.

O26 Population pharmacokinetic meta-analysis of individual data to design the first randomized efficacy trial of vancomycin in neonates and young Infants

Population Pharmacokinetic Meta-Analysis of Individual Data to Design the First Randomized Efficacy Trial of Vancomycin in Neonates and Young Infants

How to use vancomycin optimally in neonates: remaining questions

Optimization of Vancomycin Initial Dosing Regimen in Neonates Using an Externally Evaluated Population Pharmacokinetic Model

Determination of vancomycin exposure target and individualised dosing recommendations for neonates: model-informed precision dosing

External Evaluation of Population Pharmacokinetic Models of Vancomycin in Neonates: the Transferability of Published Models to Different Clinical Settings.

Use of antibacterial agents in the neonate: 50 years of experience with vancomycin administration.

Clinical Utility and Safety of a Model-Based Patient-Tailored Dose of Vancomycin in Neonates.

Therapeutic Guidelines for Prescribing Antibiotics in Neonates Should Be Evidence-Based: a French National Survey

Evaluation of a vancomycin dosing protocol for intensive care unit patients.

Role of fluid status markers as risk factors for suboptimal vancomycin concentration during continuous infusion in neonates: an observational study

Predictive Performance of Pharmacokinetic Model-Based Virtual Trials of Vancomycin in Neonates: Mathematics Matches Clinical Observation

[Dosing regimens of antibiotics in neonates: Variations in clinical practice and what should be done?].

Impact of model-informed precision dosing in adults receiving vancomycin via continuous infusion: a randomized, controlled clinical trial

Index for the appropriate vancomycin dosing in premature neonates and infants

Dose optimization and target attainment of vancomycin in children

Therapeutic drug monitoring in neonates

International Survey of Antibiotic Dosing and Monitoring in Adult Intensive Care Units.